PharmaDEXI
ActiveSummary
The computed 12-month bankruptcy probability of PharmaDEXI is 13.5% (high). For PharmaDEXI, at least two filing cycles of the annual accounts are missing. The 2023 annual accounts show negative equity (-€40,156) and a net result of -€14,540. The company has been active since 2021 and the Belgian Official Gazette contains no insolvency or warning signals.
Financials · financial year 2023, micro format
2024 annual accounts not yet filed, deadline passed on 31 July 2025 Financial year closed on 31 December 2024; filing due at the latest 7 months after the close (Companies Code art. 3:10). 2 financial years without a filing since the last one filed. Source: NBB filings, as of 25 October 2026.
2022 to 2023, 2 financial years
The operating result stays negative: a loss of €14,459 in 2023 against €30,539 in 2022; the loss shrinks.
What the company sold each financial year and what was left of it. A loss stands below the zero line.
What the company owns (total assets), how much of it is its own (equity) and how much it owes.
Short-term assets minus short-term debts. Above zero the company can pay its bills in the short term.
Use the arrow keys on the chart for the figures per year.
| Line | 2022 | 2023 | Change |
|---|---|---|---|
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €14,559 | €2,817 | ▼ 80.6% |
| Other operating charges640/8 | €62 | €2,390 | ▲ 39× |
| Gross operating margin9900 | -€15,918 | -€9,252 | ▲ 41.9% |
| Operating profit (loss)9901 | -€30,539 | -€14,459 | ▲ 52.7% |
| Financial charges65/66B | €77 | €81 | ▲ 5.2% |
| Recurring financial charges65 | €77 | €81 | ▲ 5.2% |
| Profit (loss) for the period before taxes9903 | -€30,616 | -€14,540 | ▲ 52.5% |
| Profit (loss) for the period9904 | -€30,616 | -€14,540 | ▲ 52.5% |
| Profit (loss) for the period to be appropriated9905 | -€30,616 | -€14,540 | ▲ 52.5% |
| Line | 2022 | 2023 | Change |
|---|---|---|---|
| Assets | |||
| Total assets20/58 | €31,477 | €29,457 | ▼ 6.4% |
| Fixed assets21/28 | €20,154 | €17,337 | ▼ 14.0% |
| Intangible fixed assets21 | €19,254 | €16,437 | ▼ 14.6% |
| Financial fixed assets28 | €900 | €900 | = |
| Current assets29/58 | €11,323 | €12,120 | ▲ 7.0% |
| Amounts receivable within one year40/41 | €11,323 | €10,472 | ▼ 7.5% |
| Trade receivables40 | €9,155 | €10,159 | ▲ 11.0% |
| Other amounts receivable41 | €2,168 | €313 | ▼ 85.6% |
| Cash at bank and in hand54/58 | - | €1,648 | - |
| Equity and liabilities | |||
| Total equity and liabilities10/49 | €31,477 | €29,457 | ▼ 6.4% |
| Equity10/15 | -€25,616 | -€40,156 | ▼ 56.8% |
| Contributions10/11 | €5,000 | €5,000 | = |
| Profit (loss) carried forward14 | -€30,616 | -€45,156 | ▼ 47.5% |
| Amounts payable17/49 | €57,093 | €69,612 | ▲ 21.9% |
| Amounts payable within one year42/48 | €57,093 | €69,612 | ▲ 21.9% |
| Financial debts43 | €4,510 | - | - |
| Credit institutions430/8 | €4,510 | - | - |
| Trade debts44 | €13,438 | €12,422 | ▼ 7.6% |
| Suppliers440/4 | €13,438 | €12,422 | ▼ 7.6% |
| Advances received on contracts in progress46 | €830 | - | - |
| Other amounts payable47/48 | €38,315 | €57,190 | ▲ 49.3% |
| Line | 2022 | 2023 | Change |
|---|---|---|---|
| Profit (loss) for the period9904 | -€30,616 | -€14,540 | ▲ 52.5% |
| + Depreciation and write-downs630 | €14,559 | €2,817 | ▼ 80.6% |
| Operating cash flow (approximation) | -€16,057 | -€11,723 | ▲ 27.0% |
| Investment in fixed assets (approximation) | - | €0 | - |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Filings with the National Bank (2)
| Financial year | Type | Filed | Reference |
|---|---|---|---|
| 31-12-2023 | micro format | 30-08-2024 | 2024-00401715 |
| 31-12-2022 | micro format | 14-08-2023 | 2023-00327013 |
Public contracts: No European public contracts awarded found since October 2016. Contracts below the EU thresholds are not in TED.